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KESAN PERLINDUNGAN KARDIO EKSTRAK TERPIAWAI DAUN 
CLINACANTHUS NUTANS TERHADAP TOKSISITI-KARDIO TERARUH 
KEMOTERAPI 
 
 
6 ABSTRAK 
 
Tujuan utama tesis ini adalah untuk mengkaji kesan perlindungan-kardio ekstrak 
terpiawai daun Clinacanthus nutans (CN) terhadap toksisiti-kardio teraruh 
kemoterapi. Di Timur Jauh, CN telah digunakan secara tradisional untuk merawat 
pelbagai penyakit termasuk herpes, kanser, tulang retak, diabetes, diuretik, jaundis, 
gigitan ular dan kegagalan buah pinggang. Walaupun terdapat beberapa produk CN di 
pasaran, masih terdapat kekurangan maklumat saintifik dari segi pemiawaian. Kajian 
ini dijalankan untuk memberikan maklumat tersebut sebagai rujukan kepada 
penyelidik lain serta pengguna produk herba berasaskan potensi ekstrak daun CN. 
Kajian kualiti dan keselamatan bahan mentah tumbuhan telah diperiksa menggunakan 
analisis gravimetri dan ujian had mikrob (MLT). Pelbagai ekstrak tumbuhan (25% 
EW, 50% EW, 75% EW, 95% EW, W) telah dipiawaikan menggunakan kaedah 
spektroskopi (UV, IR) dan kromatografi kualitatif (HPTLC) serta kromatografi 
kuantitatif (HPLC). Metabolit primer dan sekunder ekstrak CN dianalisis bagi jumlah 
flavonoid, polifenol, tanin, protein, polisakarida dan glikosaponin. Komposisi 
fitokimia kesemua ekstrak ditentukan menggunakan pelbagai teknik kolorimetri dan 
gravimetri. Ekstrak terpiawai akueus CN (CN-W) menunjukkan kandungan 
glikosaponin dan polifenol tertinggi (masing-masing 45 ± 2.82 dan 4.08 ± 0.25 
w/w%,). Vitexin, isovitexin, orientin, isoorientin, asid galik, asid kafeik dan asid 
klorogenik telah digunakan sebagai penanda kimia untuk kajian analitikal ekstrak CN. 
Hasil kajian menunjukkan bahawa asid galik merupakan komponen utama dalam 
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semua ekstrak CN, manakala asid kafeik merupakan komponen minor. Penentuan dan 
pengkuantitian 17 asid amino bebas dalam ekstrak CN telah dilakukan dengan kaedah 
HPLC. Hasil kajian menunjukkan bahawa L-alanine adalah asid amino bebas utama 
dalam CN-W ekstrak dengan 3.05 ± 0.09 nmol/mg manakala L-glutamik adalah asid 
amino bebas minor dengan 0.66 ± 0.04 nmol/mg. Di samping itu, stigmasterol telah 
dipencil dan dicirikan daripada ekstrak metanol daun CN. Pencirian struktur 
stigmasterol telah dijalankan menggunakan pelbagai teknik termasuk teknik 
kristalografi X-ray dan NMR. Kesan sitotoksik bagi ekstrak CN terhadap jalur sel 
kanser terpilih (MCF 7, HCT 116 dan K562) dan jalur sel normal (CCD-18Co) telah 
diuji menggunakan assai MTT dan keputusan menunjukkan bahawa semua ekstrak CN 
tidak mempamerkan kesan sitotoksik terhadap jalur sel normal dan kanser (nilai IC50 
adalah lebih besar daripada 20 μg/mL). Assai radikal bebas difenilpikrihidrazil 
(DPPH) telah digunakan untuk menentukan kapasiti antioksidan daripada ekstrak 
tumbuhan. Hasil kajian menunjukkan bahawa, CN-W) mempamerkan perencatan 
tertinggi (dengan 94.33 ± 11.10% pada kepekatan akhir 62.5 µg/mL) dan nilai IC50 
paling rendah (6.48 ± 1.18 μg/mL). Ekstrak CN-W dipilih untuk kajian perlindungan-
kardio in vivo berdasarkan aktiviti antioksidan dan tahap kandungan polifenol yang 
tinggi. Kesan perlindungan-kardio bagi CN-W terhadap toksisiti teraruh kemoterapi 
telah dikaji menggunakan model toksisiti-kardio-teraruh-doksorubisin in vivo ke atas 
tikus Sprague Dawley (SD). Rawatan dos tunggal doksorubisin (25 mg/kg) ke atas 
tikus menyebabkan peningkatan aktiviti CPK dan LDH plasma (sebagai enzim 
jantung) (P < 0.001) berbanding kawalan manakala pra rawatan tikus yang dirawat 
doksorubisin dengan ekstrak CN-W (125, 250 dan 500 mg/kg) selama 28 hari, 
menunjukkan penurunan dalam aktiviti CPK dan LDH plasma (P < 0.05). Oleh itu, 
ekstrak CN-W pada semua dos mempunyai aktiviti perlindungan kardio yang tinggi 
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dalam model haiwan terhadap ketoksikan doksorubisin. Potensi (antagonis) ikatan 
penanda aktif CN (asid kaffeik, asid klorogenik, asid gallik, orientin, vitexin dan 
isovitexin) dan deksrazoksen (kawalan positif) dengan enzim CPK dan LDH telah 
dinilai dalam analisis dok untuk mengesahkan keupayaan mengikat sebatian penanda 
dengan enzim jantung secara teori. Hasil kajian menunjukkan bahawa, sebatian 
penanda daripada ekstrak CN mempunyai afiniti pengikatan yang lebih baik 
berbanding kawalan positif (deksrazoksen). Oleh itu, boleh dicadangkan bahawa 
sebatian penanda terpilih mempamerkan aktiviti perencatan terhadap CPK dan LDH 
dan boleh bertindak sebagai ejen perlindungan kardio. Untuk kajian kestabilan, CN-
W telah didedahkan kepada empat keadaan penyimpanan bagi suhu dan kelembapan 
relatif yang berbeza 30°C/75% RH, 40°C/75% RH, 50°C/85% RH dan 60°C/85% RH 
untuk tempoh enam bulan. Hasil kajian menunjukkan bahawa semua sebatian penanda 
(asid kafeik, asid klorogenik, asid galik, orientin dan vitexin) adalah lebih stabil pada 
30°C dan 40°C berbanding suhu 50°C dan 60°C. 
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CARDIO-PROTECTIVE EFFECT OF STANDARDIZED EXTRACT OF 
CLINACANTHUS NUTANS LINDAU AGAINTS DOXORUBICIN-INDUCED 
TOXICITY 
 
 
7 ABSTRACT 
 
The primary purpose of this thesis was to investigate cardio-protective effect of 
standardized leaf extract of Clinacanthus nutans (CN) against chemotherapy-induced 
cardio-toxicity. In the Far East, CN has been used traditionally to treat a wide range of 
diseases including herpes, cancer, fractures, diabetes, diuretic, jaundice, snake bites 
and kidney dysfunction. There are a number of CN products in market, however there 
is still lack of scientific evidence in terms of standardisation. Quality and safety of the 
plant raw material were examined using gravimetric analysis and microbial limit test 
(MLT). Various plant extracts (25% EW, 50% EW, 75% EW, 95% EW, W) were 
standardized using qualitative spectroscopic (UV, IR) and chromatographic (HPTLC) 
and quantitative chromatographic (HPLC) methods. Primary and secondary 
metabolites of CN extracts were analysed for their total flavonoids, polyphenols, 
tannins, proteins, polysaccharides and glycosaponins. Aqueous extract of CN (CN-W) 
showed the highest contents of glycosaponins and polyphenolics (45 ± 2.82 and 4.08 
± 0.25 w/w%, respectively). Vitexin, isovitexin, orientin, homoorientin, gallic acid, 
caffeic acid and chlorogenic acid were used as chemical markers for the analytical 
study of CN extracts. The results indicated that gallic acid is a major component in all 
CN extracts, while caffeic acid is the minor component. Determination and 
quantification of 17 free amino acids in CN extracts was done by HPLC method. The 
results showed that L-alanine with 3.05 ± 0.09 nmol/mg was the major free amino acid 
and L-glutamic with 0.66 ± 0.04 nmol/mg was the minor free amino acid in CN-W 
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extract. Stigmasterol was isolated and characterized from methanolic leaf extract of 
CN. The structural characterization of stigmasterol was carried out using X-ray 
crystallographic techniques and NMR. Cytotoxicity effect of CN extracts against 
selected cancer cell lines (MCF 7, HCT 116 and K562) and normal cell line (CCD-
18Co) was tested by MTT assay and the results showed that all CN extracts did not 
exhibit any cytotoxicity against normal and cancer cell lines (IC50 values were greater 
than 20 µg/mL). Free radical diphenylpicryhydrazyl (DPPH) assay results showed 
that, CN-W exhibited highest inhibition (with 94.33 ± 11.10% at the final 
concentration of 62.5 µg/mL) and lowest IC50 value (4.74 ± 0.05 µg/mL). CN-W 
extract was selected for in vivo cardio-protective study due to its high antioxidant 
activity and high level of polyphenolics content. Cardio protective effect of CN-W 
against chemotherapy induced toxicity was studied in in vivo model in doxorubicin 
(DOX)-induced cardio-toxicity on Sprague Dawley (SD) rats. Treatment of rats with 
a single dose of DOX (25 mg/kg) resulted in increase plasma CPK and LDH (as cardiac 
enzymes) activities (P < 0.001) in compared to control while pretreatment of DOX-
treated rats with CN-W extract (125, 250 and 500 mg/kg) for 28 days, resulted in a 
decreased in plasma CPK and LDH activities (P < 0.05). Therefore, CN-W extract at 
all doses had potent cardio-protective activity in animal models against DOX toxicity. 
Moreover, the pilot pharmacokinetics study was done on all marker compounds 
(vitexin, isovitexin, orientin, caffeic acid, chlorogenic acid and gallic acid) on Sprague 
Dawley (SD) rats. The results revealed that three glycoside flavonoids (vitexin, 
isovitexin, orientin) did not show any absorption in rat’s plasma after oral 
administration of extract even at very high dose (5000 mg/kg). Therefore, three 
phenolic compounds (caffeic acid, chlorogenic acid and gallic acid) were used for 
further pharmacokinetics study and subsequently caffeic acid presented highest 
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absorption in rat’s plasma after oral administration of CN-W extract. Binding 
(antagonistic) potential of CN active markers (caffeic acid, chlorogenic acid, gallic 
acid, orientin, vitexin and isovitexin) and dexrazoxane (positive control) with CPK and 
LDH enzymes were evaluated in the docking analysis to confirm the binding ability of 
marker compounds with cardiac enzymes theoretically. The results demonstrated that, 
all marker compounds from CN extracts had better binding affinity than the positive 
control (dexrazoxane). Therefore, it could be suggested that marker compounds 
presented in CN-W exhibited inhibitory activity against CPK and LDH and may act as 
cardioprotective agent. For stability studies, CN-W was exposed to four different 
storage conditions of temperatures and relative humidity 30°C/75% RH, 40°C/75% 
RH, 50°C/85% RH and 60°C/85% RH for six months’ period. The results showed that 
marker compounds (caffeic acid, chlorogenic acid, gallic acid, orientin and vitexin) 
are more stable at 30°C and 40°C compared to 50°C and 60°C temperature.  
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1 CHAPTER 1 
INTRODUCTION 
 
1.1 Medicinal Plants 
Medicinal plants have been probably used to heal or combat illness as old as 
humankind. For centuries Native peoples of various cultures have used plants as 
medicine for all sorts of healing. Plants were at the basis of Indian and Chinese 
medicine for millennia, and they still are to this day. It is from these roots that the 
Western pharmaceutical industry grew to be how and what it is today. 
Unfortunately, the modern view of plants is very different from what it was. We 
were once connected to nature, honored and respected nature, and tapped into its 
greatest potential, where plants were viewed and appreciated with utmost 
reverence. In modern times, we are greatly disconnected from nature, where we 
often either fear or disregard the presence and importance of plants. Most people 
cannot fathom using wild edibles today, whether for food or medicine. Likewise, 
most cannot be bothered to grow some of their own plants for culinary or medicinal 
purposes. What this all has also led to, is that we have decreased the quality of our 
environments and food supply and increased our rates of sickness and disease. This 
is why, today, a quiet, yet significant revolution is under way. More and more 
people are rekindling their connection to nature and combining the best of ancient 
wisdom and modern evolution by seeking the pure and unadulterated benefits that 
plants can offer us. During the past decades, public interest in natural therapies, 
namely herbal medicine, has increased dramatically not only in developing 
countries but mainly in industrialized countries. This has increased the international 
trade in herbal medicine enormously and has attracted most of the pharmaceutical 
companies, including the multinationals. Until a few years ago, only small 
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companies had interest in the marketing of herbal medicines. Currently, most large 
multinational companies are interested in commercializing herbal drugs. 
Phytotherapeutic agents or phytomedicines are standardized herbal preparations 
consisting of complex mixtures of one or more plants which are used in most 
countries for the management of various diseases. According to the World Health 
Organization (WHO1996a and b, 1992) definition, herbal drugs contain as active 
ingredients plant parts or plant materials in the crude or processed state plus certain 
excipients, i.e., solvents, diluents or preservatives. Usually, the active principles 
responsible for their pharmacological action are unknown. Whole herbs contain 
several hundred constituents of organic chemicals which may include fatty acids, 
sterols, alkaloids, glycosides, saponins, tannins and terpenes (Hill, 1952).  
Quality control and standardisation of herbal medicines involve several steps. 
However, the source and quality of raw materials play a pivotal role in guaranteeing 
the quality and stability of herbal preparations. Other factors such as the use of fresh 
plants, temperature, light exposure, water availability, nutrients, period and time of 
collection, method of drying, packing, storage and transportation of raw material, 
age and part of the plant collected, etc., can greatly affect the quality and 
consequently the therapeutic value of herbal medicines (EMEA, 2005; WHO, 
2002c, 1998c, 1996, 1991a, 1991b, 1990, 1988).  
 The general idea that herbal drugs are very safe and free from side effects is 
false. Plants have many constituents that some are very toxic such as the most 
cytotoxic anti-cancer plant-derived drugs, digitalis, the pyrrolizidine alkaloids, 
ephedrine, phorbol esters, etc. However, the adverse effects of most herbal drugs 
are relatively less frequent when the drugs are used properly compared with 
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synthetic drugs, but wellcontrolled clinical trials now confirm that they really exist 
(Bisset, 1994).  
1.2 Standardisation and Quality Control of Herbal Crude Drugs 
Generally, all medicines, whether they are synthetic or of plant origin, should 
fulfill the basic requirements of being safe and effective (EMEA, 2005; WHO, 
2002c, 1998c, 1996, 1991a, 1991b, 1990, 1988). According to WHO (1996a and b, 
1992), standardisation and quality control of herbals is the process involved in the 
physicochemical evaluation of crude drug covering aspects, such as selection and 
handling of crude material, safety, efficacy and stability assessment of finished 
product, documentation of safety and risk based on experience, provision of product 
information to consumer and product promotion. Attention is normally paid to such 
quality indices such as:  
1) Macro and microscopic examination: For Identification of right variety and 
search of adulterants.  
2) Foreign organic matter: This involves removal of matter other than source 
plant to get the drug in pure form.  
3) Ash values: These are criteria to judge the identity and purity of crude drug 
such as: total ash, sulphated ash, water soluble ash and acid insoluble ash etc.  
4) Moisture content: Checking moisture content helps reduce errors in the 
estimation of the actual weight of drug material. Low moisture suggests better 
stability against degradation of product.  
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5) Extractive values: These are indicative weights of the extractable chemical 
constituents of crude drug under different solvents environment.  
6) Crude fibre: This helps to determine the woody material component, and 
it is a criterion for judging purity.  
7) Qualitative chemical evaluation: This covers identification and 
characterization of crude drug with respect to phytochemical constituent. It employs 
different analytical technique to detect and isolate the active constituents. 
Phytochemical screening techniques involve botanical identification, extraction 
with suitable solvents, purification, and characterization of the active constituents 
of pharmaceutical importance.  
8) Chromatographic examination: Include identification of crude drug based 
on the use of major chemical constituents as markers.  
The processes mentioned above involves wide array of scientific 
investigations, which include physical, chemical and biological evaluation 
employing various analytical methods and tools. The specific aims of such 
investigation in assuring herbal quality are as varied as the processes employed.  It 
is the process of developing and agreeing upon technical standards. Specific 
standards are worked out by experimentation and observations, which would lead 
to the process of prescribing a set of characteristics exhibited by the particular 
herbal medicine. Hence standardisation is a tool in the quality control process. 
In this study, a local medicinal herb has been selected, namely Clinacanthus 
nutans (CN) which is locally known as ' Belalai gajah and Sabah snake grass' in 
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Malaysia, phaya yo or phaya plongtong in Thailand and Giro de flores, cocodrilo 
flor, e zui hua in Chinese language.  Clinacanthus nutans (Burm. f.) Lindau is the 
accepted name of this species and Clinacanthus nutans var. robinsonii Benoist, 
Clinacanthus burmanni Nees, Justicia nutans Burm. f. are their synonyms. It is 
distributed in Thailand, Indonesia, Malaysia, Vietnam and China (Guangdong, 
Guangxi, Hainan, Yunnan).  In Malaysia, the fresh leaves are boiled with water and 
consumed as herbal tea. It's also used for treating skin rashes and snake bites, lesions 
caused by herpes simplex virus, diabetic myelitis, fever and diuretics. In Thailand, 
an alcoholic extract of fresh leaves is used externally for treatment of skin rashes, 
snake and insect bite, herpes simplex virus (HSV), and varicella-zoster virus (VZV) 
lesions. The leaves can be consumed as raw material or mixed with other juices 
such as apple juice, sugar cane or green tea and served as fresh drink (Shahzad 
Aslam et al., 2015). 
1.3 Justification of the Research 
Clinacanthus nutans Lindau leaves (CN) have been used in traditional 
medicine for treating certain diseases such as skin rashes, scorpion and insect bites, 
diabetes mellitus, fever and diuretics but the therapeutic potential has not been 
explored for cancer prevention and treatment. Chemotherapy is the first line 
treatment of different types of cancer; however, occurrence of toxicities in patients 
with chemotherapy is a major concern. Therefore, the elimination of side effects 
and possible toxicities in cancer patients receiving chemotherapy has become a 
major task.  Despite all the known biological activities from previous work, 
emerging lay testimonies and Malaysian newspaper reports suggested that C. 
nutans possesses anticancer effects. However, these testimonies were not supported 
by scientific evidence. Therefore, it can be hypothesized that C. nutans derivatives 
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could be a source of cytoprotective antioxidant based anticancer regimen. Hence, 
the main aim in this study was to examine the antioxidant and cytoprotective effects 
of C. nutans against chemotherapy-induced toxicity.  
1.4 General Objectives  
In general, this study seeks to standardize C. nutans leaves extracts by 
optimizing new analytical methods to measure the content of primary and 
secondary metabolites in C. nutans extracts. In addition, this work is designed to 
appraise the possible in vitro anti-cancer properties of the standardized C. nutans 
extracts against selected cancer cell lines and also evaluate their antioxidant 
properties to estimate the in vivo cardioprotective effect of the most active extract 
against induced DOX cardio-toxicity based on structure activity relationship of 
marker compounds and to perform stability studies of selected C. nutans extract.  
1.5 Specific Objectives  
1) To standardize C. nutans extracts using selected markers and to optimize 
analytical methods for standardisation of C. nutans extracts  
2) To evaluate in vitro anti-cancer properties of the standardized C. nutans 
extracts versus selected cancer cell lines 
3) To estimate antioxidant properties of the various standardized extracts of 
C. nutans for best extract selection to evaluate its in vivo cardioprotective potential 
against DOX-induced cardiotoxicity 
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4) To perform molecular docking study in order to evaluate cardioprotective 
property of C. nutans extract based on structure activity relationship of marker 
compounds  
5) To perform stability of selected C. nutans extract  
1.6 Hypotheses 
C. nutans is a well-known medicinal plant in folklore medicine for the 
treatment of a variety of symptoms such as herpes infectious, inflammation, skin 
pruritis and insect bites. C. nutans contains high content of phenolics and flavonoids 
compounds and a positive correlation was observed between precense of high 
phenolic content and strong antioxidant activity (Manach et al., 2004). On the other 
hand, a natural antioxidant could be a potential therapeutic intervention (Rasmussen 
et al., 2005; Arts and Hollman, 2005; Hertog et al., 1994; Cole et al., 2005). Thus, 
it could be hypothesized that, pretreatment with standardised extract of C. nutans 
may have protective effect versus DOX-induced cardiac toxicity. 
1.7 Significance of Study  
The findings of present study provide knowledge on application of analytical 
methods for standardisation of plant materials and extracts to produce, safe and high 
quality herbal medicinal products for manufacturers and consumers in order to 
reduce cardiac toxicity in patients receiving anthracycline-based chemotherapy for 
cancer. Furthermore, this research fills the gaps between native herbal practices and 
contemporary medicinal sciences on protective effect of medicinal plant against 
cardiotoxicity. 
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2 CHAPTER 2 
LITERATURE REVIEW  
 
2.1 Clinacanthus nutans 
2.1.1 Taxonomy  
Family                     Acanthaceae Juss 
Order Lamiales Bromhead 
Genus Clinacanthus Nees 
Scientific name Clinacanthus nutans (Burm. f.) Lindau 
Clinacanthus nutans is a species of plant in Acanthaceae family. 
Acanthaceae, one of 24 families in the mint order (Lamiales) of flowering plants, 
containing approximately 220 genera and nearly 4,000 species distributed 
predominantly in tropical and subtropical regions of the world. The greater part of 
the Acanthaceae family are herbs or shrubs, but vines and trees occur as well. The 
range of habitats extends from marshes and estuaries to extremely dry situations, 
but most of these plants are found in damp tropical forests (Meyer et al., 2004). 
A diverse family, Acanthaceae has few universal characteristics among its 
members. Most have simple leaves arranged in opposite pairs, 
with cystoliths (enlarged cells containing crystals of calcium carbonate) in streaks 
or protuberances in the vegetative parts. The bisexual flowers are frequently 
bilaterally symmetrical and are usually enclosed by leaflike bracts, often coloured 
and large. Sepals and petals number five or four each and are often fused into 
tubular structures. There are usually two or four stamens that extend beyond the 
mouth of the flower, often with one to three staminodes (sterile stamens). 
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The pistil is superior (i.e., positioned above the attachment point of the 
other flower parts) and generally consists of two fused carpels (ovule-bearing 
segments) enclosing two locules (chambers), each of which has two to 
many ovules in two rows along the central axis of the ovary. The fruits are often 
exploding capsules containing seeds borne on hooks on the placenta (Smith, 1991; 
Heywood, 1993; Mabberley, 1998; Bosser & Heine, 2000; Whistler, 2000). 
Table 2.1: Common names of Clinacanthus nutans all around the world 
(Smitinand, 1980) 
Common names Language 
Belalai gajah 
Sabah snake grass 
Malay 
Twist of flowers 
Alligator flower 
E zui hua 
Chinese 
Phaya yo 
Phaya plongtong 
Thai 
 
Table 2.2: Synonyms of Clinacanthus nutans  
Clinacanthus nutans (Burm. f.) 
lindau 
Accepted name 
Clinacanthus nutans var. robinsonii 
Benoist 
Synonym 
Clinacanthus burmanni Nees Synonym 
Justicia nutans Burm. f Synonym 
 
2.1.2 Ethnopharmacology  
Clinacanthus nutans is popular due to its benefits in alternative medicine to 
cure various kinds of diseases. It has been used traditionally as antivenom, anti-
inflammatory, analgesic, antidiabetic, antirheumatism, antiviral and antioxidant 
(Sakdarat et al., 2009; Sittiso et al. 2010; Wanikiat et al., 2008; Pannangpetch et al., 
2007). In traditional medicine, fresh leaves of C. nutans has been suggested to be 
effective in treating poisonous snake and insect bites, burns, allergic reactions and 
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skin lesions caused by virus, diabetes mellitus, fever and diuretics, and Dengue 
disease (Lau et al., 2014; Kunsorn et al., 2013; Goonasakaran, 2013; Sakdarat et 
al., 2006; Sakdarat et al., 2009; Shim et al., 2013; Sujittapron et al., 2010; 
Tuntiwachwuttikul et al., 2004). It is believed that it has strong ability to neutralize 
the poison from the snake. The dried leaves are used to treat fever, diarrhea and 
dysuria (Uawonggul et al., 2011). Herpes genitalis is a sexually transmitted disease 
caused by the herpes simplex virus (HSV). This plant has long been traditionally 
used in herpes simplex virus (HSV) treatment in Thailand (Sangkitporn et al., 
1993). C. nutans is commonly used in traditional Malaysian medicine for its 
nourishing and antioxidant properties. Recently, the leaf extracts have been used 
extensively as primary sources of complementary and alternative healthcare or as 
economical in-house regimens for cancer patients (Arullappan et al., 2014; Yong et 
al., 2013; Wang et al., 2013). Patients have claimed that they have recovered from 
cancer illness after consuming the leaves over a certain period of time. It is also 
commonly used for kidney cleanse or detoxifying purpose. 
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Figure 2.1: Pictures of Clinacanthus nutans Lindau leaves and flower 
2.2 Review of Chemical Constituents of Clinacanthus nutans 
Clinacanthus nutans contains lupeol (1), β-sitosterol (2) (Dampawan et al., 
1977), stigmasterol (3) (Dampawan 1976) Botulin (Lin et al., 1983) and myricyl 
alcohol (Boongerd 1967; Dampawan et al., 1996). It also contain six known C-
glycosyl flavones including vitexin (4), isovitexin, shaftoside (5), isomollupentin 
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7-O-b –glucopyranoside (6), orientin (7) and homoorientin isolated from the n-
BuOH and water soluble portion of the methanolic extract of the stems and leaves 
of C. nutans collected in Thailand (Teshima et al., 1997). Five sulfur-containing 
glucosides were isolated from the n-BuOH soluble portion of a methanolic extract 
of the stems and leaves of plant material (Teshima et al., 1998). A mixture of 
cerebrosides (8) and a monoacyl monogalactosyl glycerol [(2S)-1-O-linolenoyl- 3-
O-b-Dgalactopyranosylglycerol] (9) were isolated from the EtOAc-soluble fraction 
of the ethanolic extract of the fresh leaves of C. nutans (Tuntiwachwuttikul et al., 
2004). 13-hydroxy- (13-S)-phaeophytin b, Pupurin-18-phytyl ester and 
Phaeophorbide were isolated from leaves of hexane and chloroform extract of C. 
nutans (Ayudhya et al., 2001). Trigalactosyl and digalactosyl diglycerides (10) 
were isolated form the leave extract and possess anti-herpes simplex virus effect 
(Janwitayanuchit et al., 2003). Hexane and chloroform leave extract of C. nutans 
contain, 132-hydroxy- (132-S) -chlorophyll-b, 132-hydroxy- (132-R)-chlorophyll-
b,132- hydroxy-(132-S)- phaeophytin-b,132-hydroxy-(132-R)- phaeophytin-b, 
132-hydroxy-(132-S)-phaeophytin-a,132-hydroxy-(132-R)- phaeophytin-a, 
purpurin-18- phytyl ester and phaeophorbide-a (Sakdarat et al., 2006). Three 
chlorophyll derivatives (phaeophytins) (11-13) were isolated from the chloroform 
extract of Clinacanthus nutans Lindau leaves. Three of these were known 
compounds with structures related to chlorophyll a and chlorophyll b namely 132-
hydroxy- (132-R)- phaeophytin b, 132-hydroxy- (132-S)- phaeophytin-a and 132- 
hydroxy-(132-R) -phaeophytin (Sakdarat et al., 2009). 
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Table 2.3: Chemical structures of Clinacanthus nutans 
  
 
 
 
 
Lupeol (1) 
β-sitosterol (2) 
Stigmasterol (3) Vitexin (4) 
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Table 2.3: Continued 
 
 
 
 
 
Shaftoside (8) 
Orientin (6) 
Isovitexin (5) 
Homoorientin (7) 
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Table 2.3: Continued 
 
 
 
 
 
 
 
 
 
Isomollupentin 7-O-b –glucopyranoside (9) Cerebrosides (10) 
Monoacyl monogalactosyl glycerol[(2S)-1-O-
linolenoyl- 3-O-b-Dgalactopyranosylglycerol]  (11) 
Trigalactosyl and digalactosyl diglycerides (12) 
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Table 2.3: Continued 
   
 
 
 
 
Three chlorophyll derivatives (phaeophytins) (13-15) 
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2.3 Review of Biological and Pharmacological Activities of Clinacanthus 
nutans 
Clinacanthus nutans is one of the medicinal plants easily grown in Southeast 
Asia such as Malaysia, Thailand and China. This plant has attracted public interest due 
to its high medicinal values in treating skin rashes, insect and snake bits, skin lesions 
caused by virus, diabetes mellitus, fever and diuretics, and dengue disease (Lau et al., 
2014; Kunsorn et al., 2013; Goonasakaran, 2013; Sakdarat et al., 2006; Sakdarat et al., 
2009; Shim et al., 2013; Sujittapron et al., 2010; Tuntiwachwuttikul et al., 2004). The 
possibility of employing the C. nutans extract acted as an antioxidant substance to 
ameliorate the oxidative damage (Pannangpetch et al., 2007). Eight compounds 
namely 132-hydroxy-(132-S)- chlorophyll B, 132-hydroxy-(132-R)-chlorophyll B, 
132-hydroxy-(132-S)-phaeophytin B, 132-hydroxy- (132-R)-phaeophytin B, 132-
hydroxy-(132-S)- phaeophytin A, 132-hydroxy-(132-R)-phaeophytin A, purpurin 18 
phytyl ester and phaeophorbide A have been discovered (Sakdarat et al., 2006). Recent 
study found that, C. nutans extracts are antioxidant with antiproliferative effect on 
cultured human cancer cell lines (Arullappan et al., 2014; Yong et al., 2013). The anti-
cancer role of C. nutans extracts was discovered in China (Wang et al., 2013). The 
leaves of C. nutans were found to be rich in amino acids, trace elements and bioactive 
chemical constituents in China suggesting a high nutritional value of C. nutans (Yi et 
al., 2012). In China, the rare C. nutans is usually propagated by cutting propagation, 
which is low proliferation freqency. In Malaysia, Ying (2013) and Gunasekaran (2014) 
succeeded in callus induction but no result in plantlet regeneration. 
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2.3.1 Antioxidant Effects  
The ethanol extract of the dried leaves was tested for antioxidant activity through 
DPPH, FRAP and the intracellular antioxidant activity assays. Moreover, the 
protective effect of the extract on rat RBC against 2,2′′-azobis(2- amidinopropane) 
hydrochloride (AAPH) was studied. The results clearly demonstrated significant 
antioxidant activity of the extract. Furthermore, the extract protected RBCs against 
AAPH-induced hemolysis with an IC50 of 359.38±14.02 mg/ml, suggesting that C. 
nutans may protect oxidative damage to cell components in diseased conditions 
(Direkbusarakom et al., 1998). In another experiment, the antioxidant activity of 
different extracts of C. nutans was also reported by Pannangpetch et al. (2007). Yuan 
et al. (2012) studied the ethanol extract of the leaves for antioxidant activity and its 
protective effects on the integrity of plasmid DNA in Escherichia coli. The results 
revealed better retention of the integrity of super-coiled plasmid DNA under riboflavin 
photochemical treatment when compared with the extracts of green tea. 
2.3.2 Antiviral Activity 
The effect of ethyl acetate extract of the leaves was tested on HSV type 1 strain 
F (HSV-1F) using plaque reduction assay. The extract completely inhibited the HSV-
1F plaque formation with IC50 value of 7.6 μg/ml. The study further suggested that 
the antiviral mode of action of the crude extract may be due to the virucidal activity 
through inhibition of the viral attachment or the penetration (Thongchai et al. 2008). 
In another study by Direkbusarakom et al. (1998) the antiviral activity of ethanolic 
extract of C. nutans on yellow-head rhabdovirus (YRV) in black tiger shrimp (Penaeus 
monodon) was investigated. The results indicated that the extract inhibited YRV in 
vitro with a minimum concentration of 1µg/ml suggesting that C. nutans extract 
(1g/kg) mixed with pallet feed could be ideal to control YRV infection in shrimps. 
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Kunsorn et al. (2013) studied the difference between C. nutans and C. siamensis 
by assessing characteristics, molecular aspect through genomic DNA extraction and 
evaluation of their anti-herpes simplex virus (HSV) type 1 and type 2 activities. The 
antiviral activity of n-hexane, dichloromethane and methanol extracts was performed 
using plaque reduction assay and their cytotoxicity was studied on Vero cells through 
MTT assay. The results revealed that the combination of macroscopic, microscopic 
and biomolecular methods will be helpful for their identification and both the plants 
were found to possess anti HSV activity against type 1 and type 2 virus. 
2.3.3 Cytotoxicity Activity 
The aqueous extract of the C. nutans leaves is reported to possess cytotoxicity 
effect on vero cell cultures with a CD50 of 2828 mcg/ml (Yong et al. 2013). The in 
vitro cytotoxic, antioxidant and antimicrobial activities of the petroleum ether, ethyl 
acetate and methanol extracts and semi-fractions of C. nutans leaves were studied by 
several researchers (Arullappan et al.  2014) against HeLa and K-562 cell lines by 
MTT assay and antioxidant activity by DPPH assay. The sub fractions collected from 
ethyl acetate extract were tested against Bacillus cereus, Escherichia coli, Salmonella 
enterica Typhimurium and Candida albicans. The results revealed strongest cytotoxic 
activity of the petroleum ether extract against HeLa and K-562 cells with IC50 of 18.0 
and 20.0 μg/mL, respectively and highest radical scavenging activity among other 
extracts. In MIC assay, all the extracts and fractions showed inhibition against all 
tested microorganisms. 
2.3.4 Anti-inflammatory and Analgesic Effects 
The possible anti-inflammatory activities of methanolic extracts of Barleria 
lupulina and C. nutans was studied by Wanikiat et al. (2008) through two neutrophil-
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dependent acute inflammatory models (carrageenan-induced paw oedema and ethyl 
phenylpropiolate-induced ear oedema) in rats. The study was further extended to 
investigate the effects of the tested extracts on human neutrophil responsiveness, in 
order to elucidate underlying cellular mechanisms. The results revealed significant 
inhibitory dose-dependent effects in both the models with a significant inhibition of 
myeloperoxidase (MPO) activity in the inflamed tissues. The anti-inflammatory 
activity of the extracts is believed to be associated with reduced neutrophil migration. 
In a separate study performed by Satayavivad et al. (1998) the significant anti-
inflammatory and analgesic activities of the butanol extracts of C. nutans leaves is also 
reported. 
2.3.5 Immunomodulatory Effects 
The immunomodulatory capabilities of the ethanolic extract of the leaves of C. 
nutans were investigated on cell-mediated immune response (CMIR) through its 
effects on lymphocyte proliferation, natural killer (NK) cell activity and cytokine 
production of human peripheral blood mononuclear cells. The findings of the study 
indicated that the lymphocyte proliferation was significantly increased with decrease 
in activity of NK cells and increase in the level of IL-4. Further, the findings suggested 
that the effect of the extract on human CMIR may be partially because of the release 
of IL-4 from peripheral blood mononuclear cells (Sriwanthana et al. 1996). Another 
study performed by Thamaree et al. (2001) reported the interleukin-1-beta (IL-1β) 
release inhibition of the ethanol extract of the leaves when tested on human blood. 
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2.3.6 Antidiabetic Effects 
 Wong et al. (2014) were investigated the antioxidant and antiglucosidase 
activities of six tropical medicinal plants including C. nutans. Results of the study 
exerted that C. nutans possesses antioxidant and α-glucosidase inhibitory activity. 
2.3.7 Wound Healing Effects 
Roeslan et al. (2012) performed in vitro wound healing assay through migration 
rate of human gingival fibroblast (HGF) supplemented with hexane and chloroform 
extracts of C. nutans. The results indicated that the extracts did not give any effect on 
HGF proliferation, but enhanced the migration rate, suggesting the potential 
therapeutic effect on periodontal disease. 
2.3.8 Anticancer Activity  
The antiproliferative effects of chloroform, methanol, and aqueous extracts of 
the C. nutans leaves were performed by Yong et al. (2013) on HepG2, IMR32, NCL-
H23, SNU-1, Hela, LS-174T, K562, Raji, and IMR32 cancer cells using MTT assay. 
The chloroform extract exhibited the highest antiproliferative effect on all cell lines in 
a concentration dependent manner except on IMR-32 cells. In another study done by 
Na-Bangchang et al. (2012) the anticancer and immunostimulating activities of one of 
the most popular Thai folkloric remedies were investigated for cancer treatment. The 
remedy included of a mixture of parts from five different plants (namely whole part of 
Polygala chinensis, Ammania baccifera, stems and leaves of C. nutans, rhizomes of 
Canna indica and Smilax corbularia), and five animals (namely scales of Manis 
javanica, spines of Hystrix brachyuran, Damonia subtrijuga and sternums of Trionyx 
cartilajineus) respectively. In this study decoction of the remedy was examined for the 
activities. The cytotoxic activity was investigated in vitro in KB cells and in vivo in 
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mammary cancer-bearing rat (induced by 7, 12 DMBA at a single oral dose of 150 
mg/kg body weight) and in cervical cancer xenograft nude mouse models. Acute and 
subacute toxicity tests were performed following intraperitoneal and/or oral dose 
administration. Therefore, it was concluded that the remedy was well tolerated in both 
acute and subacute toxicity tests and possess significant anticancer activity and 
activated NK cell activity. Furthermore, in the study conducted earlier by Thongrakard 
and Tencomnao (2010) the modulatory effects of ethanolic extract of C. nutans on 
IFN-γ/TNF-α caused HaCaT apoptosis and correlate with the natural phenolic 
contents. The results demonstrated that the C. nutans extract (1 and 100 μg/ml), 
significantly inhibited the IFN-γ/TNF-α induced HaCaT apoptosis but these findings 
might not be directly implicated to its natural phenolic content.  
2.4 Definition of Cardiac Toxicity 
Cardiac toxicity is damage to the heart by harmful chemicals. Cardiotoxicity is 
one of the most important adverse reactions of chemotherapy which is used for cancer 
treatment, leading to an important increase of morbidity and mortality (Cardinale et 
al., 2010; Steinherz et al., 2007). Cardiotoxicity includes a wide range of cardiac 
effects from small changes in blood pressure and arrhythmias to cardiomyopathy. In 
the literature different mechanisms of chemotherapy induced cardiotoxicity are 
postulated including cellular damage due to the formation of free oxygen radicals and 
the induction of immunogenic reactions with the presence of antigen presenting cells 
in the heart. Moreover, the influence of the cytotoxic agent on certain phospholipids, 
especially cardiolipin, may also explain the development of cardiotoxicity (Hatch and 
McLarty, 2006). 
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Myocardial damage is commonly known as cardiotoxicity, cardiomyopathy or 
cardiotoxicity, a medical emergency that occurs when blood supply to the part of heart 
is interrupted. The resulting ischemia causes damage and death of heart tissue. It is 
commonly seen with chemotherapy and medications taken to control existing diseases. 
Myocardial toxicity may cause arrhythmias or it can develop into heart failure, means 
the heart muscle cannot pump with enough force to supply the body with blood 
containing essential oxygen and nutrients. In more serious cases it results in congestive 
heart failure, heart attack, or death (Marieb and Nicpon, 2003). 
Data on the mechanism of the appearance of cardiac dysfunction during 
chemotherapy and the susceptibility of patients to develop cardiotoxicity are scarce 
(Brana and Tabernero, 2010; Khakoo et al., 2010). Some studies suggest that patients 
without known cardiovascular history may develop symptomatic heart failure in direct 
connection to the cumulative dose received, affirmation which has led to the use of 
reduced doses of chemotherapy and, therefore, to a reduction in their efficiency 
(Jensen, 2006). But also under these circumstances, there is a risk of cardiotoxicity 
induced by chemotherapy, risk which cannot be foreseen by the cumulative dose. 
Moreover, the cardiac alteration is very frequently subclinical and it can appear early 
(during therapy), late (during the first year after therapy) or very late (more than one 
year after finishing therapy) (Jiji et al., 2012). Consequently, better understanding of 
pathophysiology and early diagnosis of subclinical cardiac dysfunction in patients 
under chemotherapy, as well as the close cardiac monitoring during antineoplastic 
treatment is essential in order to reduce cardiotoxicity. Since, cardiotoxicity resulting 
from direct myocyte damage and has been a known complication of cancer treatment. 
Therefore, better understanding of cancer definition and its treatment might be useful 
way for studying the acute and long-term cardiotoxicity in cancer treatment modalities.  
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2.5 Definition of Cancer  
Cancer is the name given to a collection of related diseases. In all types of cancer, 
some of the body’s cells begin to divide without stopping and spread into surrounding 
tissues. Cancer can start almost anywhere in the human body, which is made up of 
trillions of cells. Normally, human cells grow and divide to form new cells as the body 
needs them. When cells grow old or become damaged, they die, and new cells take 
their place. When cancer develops, however, this orderly process breaks down. As 
cells become more and more abnormal, old or damaged cells survive when they should 
die, and new cells form when they are not needed. These extra cells can divide without 
stopping and may form growths called tumors (Cella and Tulsky, 2009). Many cancers 
form solid tumors, which are masses of tissue. Cancers of the blood, such as leukemias, 
generally do not form solid tumors. Cancerous tumors are malignant, which means 
they can spread into, or invade, nearby tissues (Fearon and Vogelstein, 1990). 
Moreover, as these tumors grow, some cancer cells can break off and travel to distant 
places in the body through the blood or the lymph system and form new tumors far 
from the original tumor. Unlike malignant tumors, benign tumors do not spread into, 
or invade, nearby tissues (Gallup and Talledo, 1987). Benign tumors can sometimes 
be quite large. However, when they are removed, they usually don’t grow back, 
whereas malignant tumors sometimes do (Brown et al., 1993). Unlike most benign 
tumors elsewhere in the body, benign brain tumors can be life threatening (Samii, 
1992; DeMonte et al., 1994; Coulwell et al., 1996, Samii et al., 1996, 1997; George, 
1997; Natarajan et al., 2007). Cancer cells differ from normal cells in many ways that 
allow them to grow out of control and become invasive. One important difference is 
that cancer cells are less specialized than normal cells. That is, whereas normal cells 
mature into very distinct cell types with specific functions, cancer cells do not. This is 
